In this context, we leveraged BRCA2 and PARP as a synthetic lethal target pair to consolidate the use of small molecule inhibitors of RAD51-BRCA2 protein-protein interaction as inducers of the BRCAness phenotype that sensitizes <i>BRCA2</i>-functional cancer cells to PARP inhibitors. Here, RAD51 is linked to cancer.